Clinical Trial: A Phase 1 Study of HCB303 in Participants With Advanced Malignancies

U.S., Oct. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07859228) titled 'A Phase 1 Study of HCB303 in Participants With Advanced Malignancies' on Sept. 29.

Brief Summary: A Phase 1, Open-label, Multi-regional, Multicenter, Dose escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of HCB303 in Participants with Advanced Malignancies

Study Start Date: Feb. 28, 2027

Study Type: INTERVENTIONAL

Condition: Advanced Malignancies

Intervention: DRUG: HCB303

Dose escalation from 0.03 mg/kg to 30 mg/kg.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: FBD Biologics Limited

Published by HT Digital Content Services with p...